Impact Of Rising Brain Disorder Cases On The Market Growth: Strategic Insights Driving Glioblastoma Multiforme Market Momentum in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Glioblastoma Multiforme Market Size By 2025?
The valuation of the glioblastoma multiforme sector has shown robust expansion over the preceding years, projected to advance from its 2024 figure of $1.59 billion to $1.7 billion by 2025, reflecting a compound annual growth rate (CAGR) of 7.3%. This historical period's upward trajectory is largely attributable to several key factors, including the escalating frequency of glioblastoma multiforme diagnoses, enhancements in medical infrastructure, heightened public and professional awareness, improved accessibility to cutting-edge treatment modalities, and the demographic shift towards an older population.

How Big Is the Glioblastoma Multiforme Market Size Expected to Grow by 2029?
Anticipation surrounds the glioblastoma multiforme sector, projecting considerable expansion ahead, reaching a valuation of $2.27 billion by 2029, characterized by a compound annual growth rate of 7.5%. This upward trajectory is fundamentally driven by a greater incidence of malignancies affecting the brain and nervous system, the growing adoption of specialized surgical methodologies, heightened public and professional awareness, earlier disease detection capabilities, and a surge in research and development endeavors. Key shifts expected to shape this market over the projection timeframe encompass progress in medical technology applications, improvements in diagnostic imaging modalities, the rise of tailored therapeutic approaches, the integration of artificial intelligence for diagnostic support, alongside broader scientific and technological breakthroughs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Which Key Market Drivers Powering Glioblastoma Multiforme Market Expansion and Growth?
The increasing incidence of brain disorders is anticipated to propel the glioblastoma multiforme market forward. A brain disorder signifies an affliction impacting either the architecture or operation of the brain, resulting in deficits in cognition, emotion, or physical capabilities. This surge in brain disorder prevalence stems from several contributors, including the aging of the general population, extended lifespans, alterations in lifestyle habits, and enhancements in diagnostic technologies. Gaining deeper insight into brain disorders facilitates progress in glioblastoma multiforme (GBM) research, paving the way for enhanced early identification methods, novel therapeutic approaches, and superior results for those affected. Scientific investigation into neurological ailments allows researchers to identify genetic and molecular connections that play a role in GBM formation. To illustrate this trend, data from Dementia Australia, a non-profit based in Australia, indicated that close to 433,300 Australians were living with dementia in February 2025, with estimates suggesting this figure will climb to 812,500 by 2054; moreover, about 29,000 individuals in 2025 are affected by younger-onset dementia, a number projected to grow to 41,000 by 2054. Consequently, the expanding burden of brain disorders will serve as a significant catalyst for the expansion of the glioblastoma multiforme market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Glioblastoma Multiforme Market?
Leading corporations within the glioblastoma multiforme arena are prioritizing the creation of sophisticated treatment modalities, notably CAR T-cell therapies, as a means to tackle the considerable gaps in care for this aggressive malignancy. This particular immunotherapy approach entails the genetic alteration of an individual's T-lymphocytes to enhance their capability to locate and eliminate cancerous cells with greater precision. As an illustration, in the month of June 2023, Chimeric Therapeutics Limited, a biotechnology entity situated in Australia, initiated a Phase IB study for their CHM 1101 (CLXT CAR T) treatment intended for patients experiencing recurrent or advancing glioblastoma multiforme (GBM). This multi-site investigation is designed to ascertain both the tolerability and effectiveness of the treatment while simultaneously establishing the optimal dosage level for subsequent Phase 2 testing. Preliminary findings from the Phase 1a segment indicated that the disease remained stable, and this forthcoming trial seeks to leverage those outcomes to facilitate progression toward a pivotal registration study and gather necessary input from regulatory bodies.

What Are the Emerging Segments in the Glioblastoma Multiforme Market?
The glioblastoma multiformemarket covered in this report is segmented -

1) By Drug Class: Chemotherapy Agents; Temozolomide; Carmustine; Lomustine; Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI); Computed Tomography Scan (CT Scan); Biopsy; Other Diagnostic Tools
3) By Treatment Type: Surgery; Radiation Therapy; Chemotherapy; Immunotherapy; Tumor Treating Field Therapy; Other Treatment Types
4) By End-User: Hospitals; Cancer Research Institutes; Ambulatory Surgical Centers; Other End-Users

Subsegments:
1) By Chemotherapy Agents: Alkylating Agents; Platinum-Based Agents; Antimetabolites
2) By Temozolomide: Branded (Temodar); Generic Temozolomide
3) By Carmustine: Injectable Carmustine; Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine); Generic Lomustine
5) By Other Drug Classes: Targeted Therapy; Immunotherapy; Tumor-Treating Fields (TTF) Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21191&type=smp

Who Are the Global Leaders in the Glioblastoma Multiforme Market?
Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

Which are the Top Profitable Regional Markets for the Glioblastoma Multiforme Industry?
North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21191

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.